citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ataxia, or FA. The investment bank noted that concerns about nomla's safety and ...

At this point, there are several therapies which are coming along, a large trial called the ExRx trial, which included the nutraceutical, nicotinamide riboside has finished. The data are not yet ...

Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...

(NASDAQ: NASDAQ:PTCT) received confirmation that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for vatiquinone, designed to treat Friedreich’s ataxia (FA) in ...

has accepted its New Drug Application (NDA) for vatiquinone, designed to treat Friedreich's ataxia (FA) in children and adults. The FDA has granted the application Priority Review status ...

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...

has accepted for review the Company's New Drug Application (NDA) for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA) and has granted Priority Review. This ...

Ataxia is caused by damage in cerebellum, leading to poor muscle control. Know the causes and types of ataxia that can lead to other health complications. Ataxia is a condition caused by damage in ...